Complement Factor H Inhibitors Targeting SCR 19 for Tumor Lysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting specific pathways in lung cancer often lead to resistance due to tumor heterogeneity and clonal evolution, and humoral immunity against tumor-associated antigens has not been fully exploited for effective treatment.
Innovation Solution
Development of antibodies or antibody fragments that specifically bind to a reduced form of Complement Factor H (CFH) protein, particularly targeting the SCR 19 domain, to enhance complement-dependent lysis of cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies targeting specific pathways are used, then initial response is achieved in select individuals, but resistance develops due to tumor heterogeneity and clonal evolution
Solution Approach 1:
The patent segments the CFH protein into specific epitopes (SCR 19 domain) and targets them with specialized antibodies. This segmentation allows the immune system to attack specific vulnerable regions of the tumor-associated protein, potentially overcoming tumor heterogeneity by focusing on conserved epitopes that may be shared across different tumor clones.
Solution Approach 2:
The patent identifies and targets CFH protein expression as a preliminary marker before cancer progression. By detecting and responding to CFH expression early in tumor development or progression, the therapy can prevent further tumor growth before resistance mechanisms fully establish, addressing the timing issue in cancer treatment.
2Adaptability or versatility
If humoral immunity against tumor-associated antigens is exploited, then therapeutic potential is recognized, but effectiveness is limited due to low concentration or low affinity of antibodies
Solution Approach 1:
The patent changes the affinity parameter of the antibodies by selecting and optimizing antibody clones with high affinity for the CFH epitope. Through affinity maturation or selection processes, the antibodies achieve nanomolar or picomolar affinity, transforming the weak humoral response into a potent therapeutic mechanism that can effectively target tumor cells.
Solution Approach 2:
The patent uses monoclonal antibody technology to create identical copies of the high-affinity antibody clone. This allows for consistent, reproducible production of antibodies with optimized affinity and specificity, overcoming the variability and low effectiveness of natural humoral responses while maintaining the adaptability of targeted immunity.
3Power
If antibodies bind to reduced form of CFH protein, then complement-dependent lysis of cancer cells is enhanced, but specificity and lack of cross-reactivity must be maintained
Solution Approach 1:
The patent focuses the antibody binding to a specific local region (SCR 19 domain) of the CFH protein rather than the entire protein. This localized targeting ensures high complement-dependent lysis activity at the binding site while maintaining overall antibody specificity, as the epitope is distinct from other CFH regions that might cross-react with autoantigens.
Solution Approach 2:
Instead of trying to avoid all cross-reactivity broadly, the patent inverts the approach by precisely defining and targeting a unique epitope sequence (PIDNGDIT) that is less likely to cross-react. By making the binding site more specific rather than broader, the patent achieves both high lysis activity and reduced cross-reactivity with autoantigens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies increase C3b deposition and complement-dependent lysis of cancer cells, providing a therapeutic approach to inhibit tumor growth and enhance treatment efficacy.
Implementation Method 1
an isolated antibody or antibody fragment which immunospecifically binds to a reduced form of complement factor H (CFH) protein
Implementation Method 2
The antibodies increase C3b deposition and complement-dependent lysis of cancer cells
Data Source
AI summary
Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.